**[미래에셋 제약/바이오 김승민]**
**11/20 Daily**

[https://t.me/bioksm](https://t.me/bioksm)


 **글로벌 바이오/제약**
────────────────────
 [사노피, 미국 제약사 인스메드 인수 추진 중](https://news.google.com/rss/articles/CBMiugFBVV95cUxPaGxYRUFQT3loMmZMQlRWYW5NNlExc3g5WHc5UkNfSkxUaWJtbFhXU0IzeHp2TVdicUV6b1A1UGtMNVd1UVFWT1lVTThMVE1xdzU5U3dkOHlqZ3RrS3FCQkdCN1ZEYkVzdUpJRlVJNUpsMVdNcTY1eC12RVFFQTNQNXc5Y2FFNVJwbm53dUROV0pJUzBDaTdxV3dlaGZMREV5cWhaeTBjYnJtUFFfRE1RV2RLVzlaeThnRkE?oc=5)

 [DISCO, 애브비와 AND-gated bispecific 딜 체결, 최대 25억 달러 규모](https://news.google.com/rss/articles/CBMiekFVX3lxTFBJVGIxTG5HSER2WUZ6S2VOVFFYMWVhTlRpV3RYcWNhaEZtRkJpV0xLQ21Td2xqQ3BYUTN1Mk1iV25ZWjRoWjU3NEdhXy1lSzNQVk4wRXFsODJ1MlVFanI3M1REYVQ2QVYtT0tYTGE5VjhhZXV4LUhkYVpB?oc=5)

 [FDA, 사노피 가우셰병 신경증상 치료제 승인](https://news.google.com/rss/articles/CBMiU0FVX3lxTFBDNHdiSUVhdFhJR2diS3l1cEU5TmkwTDZiZXlRbW9IVmEwWjRNNVJSMnh0ZGRSNTBmQ3Y3MDZiOVBqZW1wTG0tS0lZTVB3ZG13dXhr?oc=5)

 [FDA, 리제네론의 전신성 중증근무력증 치료제 승인](https://news.google.com/rss/articles/CBMizgFBVV95cUxQaDRQczEtLVVNQktZdUFFUG9SSHYzaWlHTUlvMUwwOTNWZGtRNEV2X0lway0wUzVubjlCRnA2dlFMbDU3R0xyb0N6X2JtMjZIYmVmdEozeWh3RGRDWXU5eHRJcTlTbGZFRWFrLXNYZmd2UElLeDJ5eDdVTk1wUlp4MzNNRm5lR3JWUF9XNTdSWFJiOVY1RzhDYmVoVnZabkNqdFdIdEJWeTMxMlZidGROdW5FbGE3YzNGTGxYWk5Qck92aDR1VEZNbWl2QWlZZw?oc=5)

 [존슨앤존슨, 카플리타 양극성 조증 적응증으로 FDA 승인 신청 — 다섯 번째 잠재 적응증](https://www.jnj.com/media-center/press-releases/johnson-johnson-seeks-u-s-fda-approval-for-caplyta-in-bipolar-mania-marking-fifth-potential-indication)

 [아스트라제네카 claudin 18.2 표적 ADC 위암 적응증, FDA 신속 검토 승인](https://news.google.com/rss/articles/CBMiU0FVX3lxTE1VY0dnRndKUnhIdXd6dHZhcXJpZWRJRnl1Wld6bEFINDkzaHBUZWwxcHpZRHZSbDk3WHVxV0dtQ0xYYzQ1NWVBR3RvaDdTSURfbU9j?oc=5)

 [바이오헤이븐의 FGFR3 표적 ADC 'BHV-1530', FGFR3 변이 요로상피암 및 두경부암에서 임상 활성 및 반응 확인 - ENA 2026 구두 발표](https://news.google.com/rss/articles/CBMiU0FVX3lxTE9PQ3ZoYzlHcThkb1Bjb0oyQnc0Q3ExVjU2eFZTcDY4YXZzODRMWFlPR18yUmExV1V2dzdyZUl1alhLX1hFdVFEZEZENUFiT2x3UWJ3?oc=5)

 [리믹스 테라퓨틱스, REM-422 1상 최신 긍정 데이터 공개 - 2026 EORTC-NCI-AACR 심포지움](https://news.google.com/rss/articles/CBMiU0FVX3lxTE5fQTRxWXQxUkRBTEgtTTF1aGtvcndIOC1jUnlYS2c5dFBVWVdUUEMzb09aN01qQWo5MnZQbFl5dDZyTkNrZEMwckplaWh5WlBSeHFB?oc=5)

 [BMS, ASH 2026에서 혈액암 및 희귀 혈액질환 전반의 임상 성과 공개](https://news.google.com/rss/articles/CBMiU0FVX3lxTE81eGxvazFNc3dxSWlhYnlzaGJPeU01UTVoRUhzNEVqU1BIMHVFSEk1Tzd6a0VGaWxxaFFyNHI4d0Z4NnVaUU9heS1JR1BGMUJGeWVN?oc=5)

 [암젠 다졸리베프, 쇼그렌 증후군 3상 성공 — 류마티스 의사들의 임상적 의의 평가](https://news.google.com/rss/articles/CBMiU0FVX3lxTE5jQ1o1dDhMYlAxUkNwelJjOE1lbkwzT2FvMnBVcFlhcTVKekZ5V0RrREFLNzVxcl9TbkJ6aWhWV2xENF8xN2dQLTh1ampiLXdWNWNn?oc=5)


 **한국 바이오/제약**
────────────────────
 [알테오젠 '키트루다SC', 美 특허심판 14건 모두 이겼다 - 한국경제](https://news.google.com/rss/articles/CBMiWkFVX3lxTE4tVjZRZ1h5alRpUzdmTGRVZnA0cTh6eEpMbkNCbzlVWXUxdk5SOEE4MFYxMGM2b3FXR2gzaGdsZDZiNmdOajExcnYweG9JTVBEb0IxMEZjbFAxUQ?oc=5)

 [낮아진 뇌졸중 콜레스테롤 목표, 한미약품 '로수젯·아모프렐' 내밀었다](https://www.hitnews.co.kr/news/articleView.html?idxno=80924)

 [[주식] 코스닥150 편입 3종, 씨어스·알지노믹스·에이프릴 '껑충'](https://www.hitnews.co.kr/news/articleView.html?idxno=80936)

 [퍼스트바이오, 급성백혈병 치료제 'FB520' 국가신약개발사업 선정](https://www.hitnews.co.kr/news/articleView.html?idxno=80920)

 [대웅제약·티온랩, 월 1회 비만치료제 'TION-L002' 임상 1상 진입](https://www.hitnews.co.kr/news/articleView.html?idxno=80917)

 [펩트론, 월 1회 세마글루타이드 'PT403' 임상 1상 IND 승인](https://www.hitnews.co.kr/news/articleView.html?idxno=80914)

 [동국·동화·동구·올릭스 등 6개사 혁신형기업 재인증…3년 연장](https://www.hitnews.co.kr/news/articleView.html?idxno=80912)

 [펩트론, 월 1회 비만치료제 ‘PT403’ 국내 임상 1상 승인 - 팜이데일리](https://news.google.com/rss/articles/CBMibkFVX3lxTE5GNHc3R1RNcGZjV2lHS2VhT1Buc1JTRk91cnRGWXAtejJuU05weG5ZRkEwOFpRVF94bGI5UEw5NW90YmY3bXl6VlNkeEs4eTJLRExtYzdpOE00ZXVmTDhiS1YwS0YwZDdVdHlLaW9B?oc=5)